Enlarge (credit: Getty | Roberto Machado Noa )
The Justice Department charged former executives of a pharmaceutical firm with fixing generic drug prices, rigging bids, and conspiring to divvy up customers, according to court documents unsealed Wednesday.
The charges, filed against two ex-Heritage Pharmaceuticals execs earlier this week in the US District Court of Eastern Pennsylvania, mark the first time the DOJ has ever gone after a generic drug maker. It likely won’t be the last.
The charges are the first fruits of an ongoing and sweeping investigation into generic drug price-fixing by the Department. Sources familiar with the matter tell Bloomberg that the investigation now involves about two dozen drugs and more than a dozen pharmaceutical companies, including Impax, Teva, and Mylan, the infamous maker of EpiPens. The DOJ’s announcement of the charges hinted that more may be coming, including yet-to-be-named co-conspirators of the former Heritage executives.
Read 7 remaining paragraphs | Comments
Source: Ars Technica – Feds begin crackdown on generic drug price fixing, nail two former execs